Endocrine Abstracts

Objectives: aGLP1 have been positioned as an effective and safe treatment in patients with Type 2 Diabetes Mellitus (DM2). The objective was to evaluate the changes metabolic and body composition at 6 months after initiation with Semaglutide weekly subcutaneous added to its basic treatment in patients with DM2.Material and Methods: Prospective observational study. Treatment was started in 42 patients with DM2, with weekly subcutaneous Semaglutide with a ...